Entrada Therapeutics Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 152

Employees

  • Stock Symbol
  • TRDA

Stock Symbol

  • Share Price
  • $4.99
  • (As of Monday Closing)

Entrada Therapeutics General Information

Description

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Contact Information

Formerly Known As
CycloPorters
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • One Design Center Place
  • Suite 17- 500
  • Boston, MA 02210
  • United States
+1 (857)
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • One Design Center Place
  • Suite 17- 500
  • Boston, MA 02210
  • United States
+1 (857)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Entrada Therapeutics Stock Performance

As of 16-Nov-2026, Entrada Therapeutics’s stock price is $4.99. Its current market cap is $196M with 39.2M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.99 $5.10 $4.11 - $16.45 $196M 39.2M 383K -$3.84

Entrada Therapeutics Financials Summary

As of 30-Sep-2026, Entrada Therapeutics has a trailing 12-month revenue of $3.98M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 72,787 118,456 258,961 219,019
Revenue 3,977 25,421 210,782 129,013
EBITDA (167,961) (153,798) 50,811 (321)
Net Income (161,386) (143,750) 65,626 (6,685)
Total Assets 266,880 377,378 526,321 469,192
Total Debt 47,313 50,932 59,207 68,230
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Entrada Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Entrada Therapeutics‘s full profile, request access.

Request a free trial

Entrada Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Entrada Therapeutics‘s full profile, request access.

Request a free trial

Entrada Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by es
Drug Delivery
Boston, MA
152 As of 2026

San Diego, CA
 

Waltham, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Entrada Therapeutics Competitors (33)

One of Entrada Therapeutics’s 33 competitors is Avidity Biosciences, a Formerly VC-backed company based in San Diego, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Avidity Biosciences Formerly VC-backed San Diego, CA
Dyne Therapeutics Formerly VC-backed Waltham, MA
PEP-Therapy Venture Capital-Backed Evry Cedex, France
Enterome Venture Capital-Backed Paris, France
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom
You’re viewing 5 of 33 competitors. Get the full list »

Entrada Therapeutics Patents

Entrada Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026151958-A1 Compounds and methods for skipping exon 51 in duchenne muscular dystrophy Pending 10-Jan-2025
WO-2026136957-A3 Compounds comprising delivery constructs comprising cyclic cell penetrating peptides for intracellular targeting of oligonucleotides Pending 20-Dec-2024
WO-2026136957-A2 Intracellular targeting of oligonucleotides Pending 20-Dec-2024
WO-2026136946-A1 Phosphorodiamidate morpholino oligomer conjugate compounds and their use in treating myotonic dystrophy type 1 Pending 20-Dec-2024
WO-2025151707-A1 Method for preparing multimers of phosphorodiamidate morpholino oligomers Inactive 11-Jan-2024 C12N15/111
To view Entrada Therapeutics’s complete patent history, request access »

Entrada Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Entrada Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Entrada Therapeutics‘s full profile, request access.

Request a free trial

Entrada Therapeutics ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

31.91 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Entrada Therapeutics’s complete esg history, request access »

Entrada Therapeutics FAQs

  • When was Entrada Therapeutics founded?

    Entrada Therapeutics was founded in 2016.

  • Where is Entrada Therapeutics headquartered?

    Entrada Therapeutics is headquartered in Boston, MA.

  • What is the size of Entrada Therapeutics?

    Entrada Therapeutics has 152 total employees.

  • What industry is Entrada Therapeutics in?

    Entrada Therapeutics’s primary industry is Drug Delivery.

  • Is Entrada Therapeutics a private or public company?

    Entrada Therapeutics is a Public company.

  • What is Entrada Therapeutics’s stock symbol?

    The ticker symbol for Entrada Therapeutics is TRDA.

  • What is the current stock price of Entrada Therapeutics?

    As of 16-Nov-2026 the stock price of Entrada Therapeutics is $4.99.

  • What is the current market cap of Entrada Therapeutics?

    The current market capitalization of Entrada Therapeutics is $196M.

  • What is Entrada Therapeutics’s current revenue?

    The trailing twelve month revenue for Entrada Therapeutics is $3.98M.

  • Who are Entrada Therapeutics’s competitors?

    Avidity Biosciences, Dyne Therapeutics, PEP-Therapy, Enterome, and Enterprise Therapeutics are some of the 33 competitors of Entrada Therapeutics.

  • What is Entrada Therapeutics’s annual earnings per share (EPS)?

    Entrada Therapeutics’s EPS for 12 months was -$3.84.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process